Da-Qiang Li
Overview
Explore the profile of Da-Qiang Li including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
96
Citations
4421
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Huang M, Cai J, Yang S, Zhao Q, Shao Z, Zhang F, et al.
Adv Sci (Weinh)
. 2025 Jan;
12(10):e2413280.
PMID: 39836524
Triple-negative breast cancer (TNBC) is a difficulty and bottleneck in the clinical treatment of breast cancer due to a lack of effective therapeutic targets. Herein, we first report that secernin...
2.
Andriani L, Ling Y, Yang S, Zhao Q, Ma X, Huang M, et al.
Cancer Lett
. 2024 Jun;
597:217008.
PMID: 38849012
Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer and it lacks specific therapeutic targets and effective treatment protocols. By analyzing a proteomic TNBC dataset, we found...
3.
Huang M, Hu S, Dong J, Deng L, Andriani L, Ma X, et al.
Cancer Res
. 2024 May;
84(16):2660-2673.
PMID: 38748783
Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer. Transcriptional dysregulation is a hallmark of cancer, and several transcriptional regulators have been demonstrated to contribute to cancer...
4.
Deng L, Liao L, Zhang Y, Yang S, Hu S, Andriani L, et al.
Sci Adv
. 2024 Apr;
10(14):eadj4009.
PMID: 38569025
Triple-negative breast cancer (TNBC) is the deadliest subtype of breast cancer owing to the lack of effective therapeutic targets. Splicing factor 3a subunit 2 (SF3A2), a poorly defined splicing factor,...
5.
Chen S, Zhang F, Zhang Y, Liao L, Deng L, Shao Z, et al.
Cancer Lett
. 2024 Jan;
586:216672.
PMID: 38280476
Triple-negative breast cancer (TNBC) is the most lethal subtype of breast cancer with no targeted therapy. Spermatid perinuclear RNA binding protein (STRBP), a poorly characterized RNA-binding protein (RBP), has an...
6.
Liao L, Deng L, Zhang Y, Yang S, Andriani L, Hu S, et al.
Clin Transl Med
. 2023 Nov;
13(11):e1480.
PMID: 38009308
Background: Triple-negative breast cancer (TNBC) presents the most challenging subtype of all breast cancers because of its aggressive clinical phenotypes and absence of viable therapy targets. In order to identify...
7.
Yang S, Liao L, Hu S, Deng L, Andriani L, Zhang T, et al.
Int J Mol Sci
. 2023 Oct;
24(19).
PMID: 37834012
Triple-negative breast cancer (TNBC) is the most fatal subtype of breast cancer; however, effective treatment strategies for TNBC are lacking. Therefore, it is important to explore the mechanism of TNBC...
8.
Hu S, Qian J, Yang S, Andriani L, Liao L, Deng L, et al.
Clin Transl Med
. 2023 Mar;
13(3):e1210.
PMID: 36967563
Background: Microtubule-targeing agents (MTAs), such as paclitaxel (PTX) and vincristine (VCR), kill cancer cells through activtion of the spindle assembly checkpoint (SAC) and induction of mitotic arrest, but the development...
9.
Deng L, Liao L, Zhang Y, Hu S, Yang S, Ma X, et al.
Cancer Lett
. 2023 Mar;
560:216124.
PMID: 36907504
Triple-negative breast cancer (TNBC), although highly lethal, lacks validated therapeutic targets. Here, we report that U2 snRNP-associated SURP motif-containing protein (U2SURP), a poorly defined member of the serine/arginine rich protein...
10.
Zhang F, Yang S, Liao L, Zhang T, Zhang Y, Hu S, et al.
Theranostics
. 2023 Feb;
13(3):973-990.
PMID: 36793866
SUMOylation regulates a plethora of biological processes, and its inhibitors are currently under investigation in clinical trials as anticancer agents. Thus, identifying new targets with site-specific SUMOylation and defining their...